This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SLGC Standard BioTools (SLGC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Standard BioTools Stock (NASDAQ:SLGC) 30 days 90 days 365 days Advanced Chart Get Standard BioTools alerts:Sign Up Key Stats Today's Range$1.93▼$2.3150-Day Range$2.10▼$2.8352-Week Range$1.73▼$3.79Volume33.91 million shsAverage Volume10.83 million shsMarket Capitalization$394.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado.Read More… Receive SLGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Standard BioTools and its competitors with MarketBeat's FREE daily newsletter. Email Address SLGC Stock News HeadlinesStandard BioTools cut to Neutral at KeyBanc on guidanceFebruary 27, 2025 | msn.comStandard BioTools announces publication on study using SomaScan PlatformJanuary 8, 2025 | markets.businessinsider.comGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.April 26, 2025 | Weiss Ratings (Ad)Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature MedicineJanuary 8, 2025 | markets.businessinsider.comStandard BioTools Inc. Reports Q3 2024 Financial PerformanceOctober 31, 2024 | markets.businessinsider.comStandard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan® 11K PlatformSeptember 24, 2024 | markets.businessinsider.comStandard BioTools And 2 Other Penny Stocks Executives Are BuyingAugust 29, 2024 | msn.comStandard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 26, 2024 | markets.businessinsider.comSee More Headlines SLGC Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Standard BioTools own? Based on aggregate information from My MarketBeat watchlists, some other companies that Standard BioTools investors own include Digital Turbine (APPS), CrowdStrike (CRWD), SoFi Technologies (SOFI), Vuzix (VUZI) and Okta (OKTA). Company Calendar Today4/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBusiness Services Industry Commercial physical research Sub-IndustryN/A Current SymbolNASDAQ:SLGC CIK1837412 Webii.cmlifesciencesspac.com Phone303-625-9000FaxN/AEmployees451Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-109,160,000.00 Net Margins-159.54% Pretax Margin-159.08% Return on Equity-24.72% Return on Assets-21.62% Debt Debt-to-Equity RatioN/A Current Ratio17.79 Quick Ratio17.29 Sales & Book Value Annual Sales$97.67 million Price / Sales4.04 Cash FlowN/A Price / Cash FlowN/A Book Value$3.00 per share Price / Book0.70Miscellaneous Outstanding Shares188,070,000Free Float160,049,000Market Cap$394.95 million OptionableOptionable Beta1.64 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:SLGC) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Standard BioTools Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Standard BioTools With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.